Skip to Content
Merck
All Photos(1)

Key Documents

SML2897

Sigma-Aldrich

Flomoxef Sodium

≥97% (HPLC)

Synonym(s):

(6R,7R)-7-[[2-[(Difluoromethyl)thio]acetyl]amino]-3-[[[1-(2-hydroxyethyl)-1H-tetrazol-5-yl]thio]methyl]-7-methoxy-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monosodium salt, 6315-S Sodium salt, FMOX Sodium salt

Sign Into View Organizational & Contract Pricing

Select a Size

10 MG
$152.00
50 MG
$612.00

$152.00

Estimated to ship on30 March 2025

Request a Bulk Order
All Photos(1)

Select a Size

Change View
10 MG
$152.00
50 MG
$612.00

About This Item

Empirical Formula (Hill Notation):
C15H17F2N6O7S2 · Na
CAS Number:
92823-03-5
Molecular Weight:
518.45
UNSPSC Code:
12352200
NACRES:
NA.77

$152.00

Estimated to ship on30 March 2025

Request a Bulk Order

Quality Level

100

Assay

≥97% (HPLC)

form

powder

color

white to beige

solubility

H2O: 2 mg/mL, clear

storage temp.

−20°C

Biochem/physiol Actions

Flomoxef is a semisynthetic oxacephem antibiotic. Flomoxef exhibit activity against epidermides, streptococci, propionibacteria, and both methicillin-resistant and -susceptible Staphylococcus aureus. Flomoxef appear to be stable to the common plasmid beta-lactamases TEM and SH4V-1 or by the betalactamases of S. aureus or B. fragilis.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000234774
0000169316
0000169317

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Chen-Hsiang Lee et al.
Infection and drug resistance, 11, 2471-2480 (2018-12-21)
Flomoxef is potentially effective against β-lactamase-producing Enterobacteriaceae because limited clinical data demonstrate its effectiveness against Enterobacteriaceae bloodstream infections (BSIs) based on its minimum inhibitory concentrations (MICs). This study was conducted to determine the optimal breakpoints based on the survival of
H C Neu et al.
Antimicrobial agents and chemotherapy, 30(5), 638-644 (1986-11-01)
6315-S, a novel difluoromethyl thioacetamido oxacephem, had in vitro activity comparable to that of cefotaxime and moxalactam against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Klebsiella oxytoca, Citrobacter diversus, Salmonella spp., and Shigella spp., inhibiting 90% at less than or equal
Jen-Jia Yang et al.
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 51(5), 681-687 (2017-07-12)
Suppression of intestinal flora by broad-spectrum antimicrobial agents facilitated risk of colonization or infection with resistant pathogen. We aimed to investigate the changes in bowel carriage of target resistant microorganisms (TRO) among patients treated with three different classes of Pseudomonas-sparing

Questions

Reviews

No rating value

Active Filters

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service